Coordination polymers and polygons using di-pyridyl-thiadiazole spacers and substituted phosphorodithioato NiII complexes: potential and limitations for inorganic crystal engineering

Coordinatively unsaturated P-substituted dithiophosphonato, dithiophosphato, and dithiophosphito complexes {[Ni?(MeO)2PS2)2] (1), [Ni((EtO)2PS2)2] (2), [Ni(MeOdtp)2] (3), and [Ni((Ph)2PS2)2] (4)} were reacted with the bis-functional ligands 3,5-di-(4-pyridyl)-1,2,4-thiadiazole (L1) and 3,5-di-(3-pyridyl)-1,2,4-thiadiazole (L2) to give the coordination polymers (1–4·L1)?, (3·L2)?, and (4·L2·2C7H8)? and the discrete dimers (1–2·L2)2, all characterised by single crystal X-ray diffraction. A comparison of the structures shows that L1 can be exploited for the predictable assembly of undulating chains independent of the nature of the NiII complex, while L2 allows for the existence of different supramolecular constructs ensuing from different ligand conformations deriving from the rotation of the pyridyl rings

Evaluation of the Bruker SMART X2S: crystallography for the nonspecialist?

An evaluation of the Bruker SMART X2S for the collection of crystallographic diffraction data, structure solution and refinement is carried out with a variety of materials with different electron densities, presenting some of the successes and challenges of automation in chemical crystallography

Higher Education in the melting pot

The idea of this book emerged from the Education Deans Forum (EDF) meeting held in Johannesburg in 2018. The forum discussed the twin issues of the 4IR and Decolonisation and how these were likely to impact the future development of Higher Education in South Africa. Essentially, this book provides scholarly analyses of a range of possible impacts of the two discourses. On one hand, the discourses are discussed as representing convergences and divergences in relation to their epistemological, ontological, axiological and methodological assumptions. On the other, they are portrayed as competing for dominance in the contemporary and future discourses in Higher Education. As a scholarly compilation of high-end research, the book is a must-read resource for academics generally and those in teacher education disciplines particularly. Issues of the automation of academic workspaces, impact of digital divides, the opportunities and constraints of the technologisation of curricula, pedagogies, teaching and learning and the intractable challenges of remote modalities of university instruction are dealt with by some of the leading thinkers in the South African academies

Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

Background &amp; Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF). Methods: Viremic patients with CHB not receiving treatment were stratified by HBeAg status and randomized 2:2:1 to TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW), selgantolimod 1.5 mg QW, or placebo. Combination therapy continued until week (W)24, followed by TAF monotherapy until W48; patients then discontinued TAF and were followed until W96 (treatment-free follow-up [TFFU] period). The primary efficacy endpoint was the proportion with ≥1 log10 IU/ml HBsAg decline at W24. Results: Sixty-seven patients received study drug; 27 were followed during TFFU. Nausea, headache, vomiting, fatigue, and dizziness were the most common adverse events. Most adverse events were grade 1. Alanine aminotransferase flares were not observed up to W48. Four patients experienced alanine aminotransferase and hepatitis flares during TFFU; all had HBV DNA increases. Selgantolimod increased serum cytokines and chemokines and redistributed several circulating immune cell subsets. No patients achieved the primary efficacy endpoint. Mean HBsAg changes were −0.12, −0.16, and −0.12 log10 IU/ml in the selgantolimod 3 mg, selgantolimod 1.5 mg, and placebo groups, respectively, at W48; HBV DNA declined in all groups by ≥2 log10 IU/ml as early as W2, with all groups rebounding to baseline during TFFU. No HBsAg or HBeAg loss or seroconversion was observed throughout TFFU. Conclusions: Selgantolimod up to 3 mg was safe and well tolerated. Pharmacodynamics and antiviral activity in viremic patients support continued study of selgantolimod in combination CHB therapies. Impact and implications: Novel therapeutics for chronic HBV infection are needed to achieve a functional cure. In this study, we confirmed the safety and tolerability of selgantolimod (formerly GS-9688, a TLR8) when administered with tenofovir alafenamide over 24 weeks in viremic patients with chronic HBV infection. Overall, declines in HBsAg levels with selgantolimod treatment were modest; subgroup analysis indicated that patients with alanine aminotransferase levels greater than the upper limit of normal had significantly greater declines compared to those with normal alanine aminotransferase levels (–0.20 vs. –0.03 log10 IU/ml; p &lt;0.001). These findings suggest a potential differential response to selgantolimod based on patients’ baseline HBV-specific immune response, which should be considered in future investigations characterizing the underlying mechanisms of selgantolimod treatment and in HBV cure studies using similar immunomodulatory pathways. Clinical trial number: NCT03615066 be found at https://www.gileadclinicaltrials.com/transparency-policy/.</p

Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

Background &amp; Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF). Methods: Viremic patients with CHB not receiving treatment were stratified by HBeAg status and randomized 2:2:1 to TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW), selgantolimod 1.5 mg QW, or placebo. Combination therapy continued until week (W)24, followed by TAF monotherapy until W48; patients then discontinued TAF and were followed until W96 (treatment-free follow-up [TFFU] period). The primary efficacy endpoint was the proportion with ≥1 log10 IU/ml HBsAg decline at W24. Results: Sixty-seven patients received study drug; 27 were followed during TFFU. Nausea, headache, vomiting, fatigue, and dizziness were the most common adverse events. Most adverse events were grade 1. Alanine aminotransferase flares were not observed up to W48. Four patients experienced alanine aminotransferase and hepatitis flares during TFFU; all had HBV DNA increases. Selgantolimod increased serum cytokines and chemokines and redistributed several circulating immune cell subsets. No patients achieved the primary efficacy endpoint. Mean HBsAg changes were −0.12, −0.16, and −0.12 log10 IU/ml in the selgantolimod 3 mg, selgantolimod 1.5 mg, and placebo groups, respectively, at W48; HBV DNA declined in all groups by ≥2 log10 IU/ml as early as W2, with all groups rebounding to baseline during TFFU. No HBsAg or HBeAg loss or seroconversion was observed throughout TFFU. Conclusions: Selgantolimod up to 3 mg was safe and well tolerated. Pharmacodynamics and antiviral activity in viremic patients support continued study of selgantolimod in combination CHB therapies. Impact and implications: Novel therapeutics for chronic HBV infection are needed to achieve a functional cure. In this study, we confirmed the safety and tolerability of selgantolimod (formerly GS-9688, a TLR8) when administered with tenofovir alafenamide over 24 weeks in viremic patients with chronic HBV infection. Overall, declines in HBsAg levels with selgantolimod treatment were modest; subgroup analysis indicated that patients with alanine aminotransferase levels greater than the upper limit of normal had significantly greater declines compared to those with normal alanine aminotransferase levels (–0.20 vs. –0.03 log10 IU/ml; p &lt;0.001). These findings suggest a potential differential response to selgantolimod based on patients’ baseline HBV-specific immune response, which should be considered in future investigations characterizing the underlying mechanisms of selgantolimod treatment and in HBV cure studies using similar immunomodulatory pathways. Clinical trial number: NCT03615066 be found at https://www.gileadclinicaltrials.com/transparency-policy/.</p

Higher Education in the melting pot

The idea of this book emerged from the Education Deans Forum (EDF) meeting held in Johannesburg in 2018. The forum discussed the twin issues of the 4IR and Decolonisation and how these were likely to impact the future development of Higher Education in South Africa. Essentially, this book provides scholarly analyses of a range of possible impacts of the two discourses. On one hand, the discourses are discussed as representing convergences and divergences in relation to their epistemological, ontological, axiological and methodological assumptions. On the other, they are portrayed as competing for dominance in the contemporary and future discourses in Higher Education. As a scholarly compilation of high-end research, the book is a must-read resource for academics generally and those in teacher education disciplines particularly. Issues of the automation of academic workspaces, impact of digital divides, the opportunities and constraints of the technologisation of curricula, pedagogies, teaching and learning and the intractable challenges of remote modalities of university instruction are dealt with by some of the leading thinkers in the South African academies

Do swimmers conform to criterion speed during pace-controlled swimming in a 25-m pool using a visual light pacer?

The purpose of this study was to investigate whether swimmers follow the instructed speed (vtarget) accurately with the aid of a commercial visual light pacer during front crawl and backstroke swimming in a 25 m pool. Ten male swimmers performed 50 m front crawl and backstroke at different speeds (controlled by a visual light pacer) in a 25 m pool. The mean speed during the 50 m swimming (vS) was quantified from the time measured by a stopwatch. The mean speed of the centre of mass during a stroke cycle in the middle of the pool (vCOM) was calculated from three-dimensional coordinates obtained from Direct Linear Transformation of two-dimensional digitised coordinates of 19 segment endpoints for each of six cameras. Swimmers achieved accurate vS in front crawl and backstroke (ICC = 0.972 and 0.978, respectively). However, vCOM for the single mid-pool sample had lower correlations with vtarget (ICC = 0.781 and 0.681, respectively). In backstroke, vCOM was slower by 4.1-5.1% than vtarget. However, this was not the case in front crawl (1.0-2.7%). With the use of a visual light pacer, swimmers can achieve accurate mean speed overall but are less able to achieve the target speed stroke by stroke

Measurement of the cosmic ray spectrum above 4×10184{\times}10^{18} eV using inclined events detected with the Pierre Auger Observatory

A measurement of the cosmic-ray spectrum for energies exceeding $4{\times}10^{18}$ eV is presented, which is based on the analysis of showers with zenith angles greater than $60^{\circ}$ detected with the Pierre Auger Observatory between 1 January 2004 and 31 December 2013. The measured spectrum confirms a flux suppression at the highest energies. Above $5.3{\times}10^{18}$ eV, the "ankle", the flux can be described by a power law $E^{-\gamma}$ with index $\gamma=2.70 \pm 0.02 \,\text{(stat)} \pm 0.1\,\text{(sys)}$ followed by a smooth suppression region. For the energy ($E_\text{s}$) at which the spectral flux has fallen to one-half of its extrapolated value in the absence of suppression, we find $E_\text{s}=(5.12\pm0.25\,\text{(stat)}^{+1.0}_{-1.2}\,\text{(sys)}){\times}10^{19}$ eV.Comment: Replaced with published version. Added journal reference and DO

Energy Estimation of Cosmic Rays with the Engineering Radio Array of the Pierre Auger Observatory

The Auger Engineering Radio Array (AERA) is part of the Pierre Auger Observatory and is used to detect the radio emission of cosmic-ray air showers. These observations are compared to the data of the surface detector stations of the Observatory, which provide well-calibrated information on the cosmic-ray energies and arrival directions. The response of the radio stations in the 30 to 80 MHz regime has been thoroughly calibrated to enable the reconstruction of the incoming electric field. For the latter, the energy deposit per area is determined from the radio pulses at each observer position and is interpolated using a two-dimensional function that takes into account signal asymmetries due to interference between the geomagnetic and charge-excess emission components. The spatial integral over the signal distribution gives a direct measurement of the energy transferred from the primary cosmic ray into radio emission in the AERA frequency range. We measure 15.8 MeV of radiation energy for a 1 EeV air shower arriving perpendicularly to the geomagnetic field. This radiation energy -- corrected for geometrical effects -- is used as a cosmic-ray energy estimator. Performing an absolute energy calibration against the surface-detector information, we observe that this radio-energy estimator scales quadratically with the cosmic-ray energy as expected for coherent emission. We find an energy resolution of the radio reconstruction of 22% for the data set and 17% for a high-quality subset containing only events with at least five radio stations with signal.Comment: Replaced with published version. Added journal reference and DO